排序方式: 共有4条查询结果,搜索用时 0 毫秒
1
1.
Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis 总被引:1,自引:0,他引:1
Samsonov MY; Nassonov EL; Tilz GP; Geht BM; Demel U; Gurkina GT; Shtutman VZ; Guseva AG; Wachter H; Fuchs D 《Rheumatology (Oxford, England)》1997,36(6):656-660
We determined serum concentrations of neopterin, soluble tumour necrosis
factor (55 kDa) receptor (sTNF-R) and soluble interleukin-2 receptor
(sIL-2R) in plasma of 44 patients with polymyositis (PM)/dermatomyositis
(DM), including 15 patients with primary PM, 13 patients with primary DM,
and 16 patients with myositis and systemic sclerosis in overlap.
Concentrations of neopterin, sTNF-R and sIL-2R were measured using
commercially available immunoassays. Serum neopterin was increased in 35 of
44 PM/DM patients (80%), sTNF-R in 14 (32%) and sIL-2R in 18 (41%)
patients, respectively. There were significant correlations between serum
neopterin and sTNF-R, sIL-2R and erythrocyte sedimentation rate (all P <
0.001). Neopterin, as well as sTNF-R and sIL-2R, did not correlate with
clinical (neuromuscular and activities of daily living scores) and
laboratory (creatine kinase levels) manifestations of myositis. Increased
serum levels of neopterin were associated with non-muscular manifestations
of PM/DM. In conclusion, serum neopterin appears to be a useful laboratory
marker for ongoing immune activation and global disease activity in PM/DM.
相似文献
2.
3.
4.
Andriana C Kaliora Maria G Stathopoulou John K Triantaf illidis George VZ Dedoussis Nikolaos K Andrikopoulos 《World journal of gastroenterology : WJG》2007,(45)
AIM: To assess the effects of mastic administration on cytokine production of circulating mononuclear cells of patients with active Crohn's disease (CD). METHODS: The study was conducted in patients with established mildly to moderately active CD, attending the outpatient clinics of the hospital, and in healthy controls. Recruited to a 4 wk treatment with mastic caps (6 caps/d, 0.37 g/cap) were 10 patients and 8 controls, all of who successfully completed the protocol. Interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), monocyte chemotactic protein-1 (MCP-1), macrophage migration inhibitory factor (MIF) and intracellular antioxidant glutathione (GSH) were evaluated in peripheral blood mononuclear cells (PBMC) before and after treatment. RESULTS: Treating CD patients with mastic resulted in the reduction of TNF-α secretion (2.1 ± 0.9 ng/mL vs 0.5 ± 0.4 ng/mL, P = 0.028). MIF release was signif icantly increased (1.2 ± 0.4 ng/mL vs 2.5 ± 0.7 ng/mL, P = 0.026) meaning that random migration and chemotaxis of monocytes/macrophages was inhibited. No signifi cant changes were observed in IL-6, MCP-1 and GSH concentrations. CONCLUSION: This study shows that mastic acts as an immunomodulator on PBMC, acting as a TNF-α inhibitor and a MIF stimulator. Although further double-blind, placebo-controlled studies in a large number of patients is required to clarify the role of this natural product, this f inding provides strong evidence that mastic might be an important regulator of immunity in CD. 相似文献
1